PMID- 23364922
OWN - NLM
STAT- MEDLINE
DCOM- 20130725
LR  - 20201209
IS  - 1097-0215 (Electronic)
IS  - 0020-7136 (Linking)
VI  - 133
IP  - 3
DP  - 2013 Aug 1
TI  - Increased expression of metadherin protein predicts worse disease-free and 
      overall survival in laryngeal squamous cell carcinoma.
PG  - 671-9
LID - 10.1002/ijc.28071 [doi]
AB  - Metadherin (MTDH) is involved in tumourigenesis and cancer progression in 
      multiple human malignancies. However, the MTDH protein has rarely been reported 
      in laryngeal squamous cell carcinoma (LSCC). The expression pattern of the MTDH 
      protein in 176 primary archival LSCC and 27 corresponding adjacent noncarcinoma 
      specimens was detected by immunohistochemistry and further correlated with 
      clinicopathological parameters. The results demonstrated that 161 (91.48%) 
      primary LSCC samples stained positive for MTDH; however, staining was barely 
      detectable in all adjacent noncarcinoma samples. Moreover, the expression of the 
      MTDH protein was significantly associated with the primary tumour site (p = 
      0.021), T classification (p = 0.002), clinical stage (I + II/III + IV; p < 
      0.001), lymph node metastasis (p < 0.001) and postoperational recurrence (p < 
      0.001). Kaplan-Meier analysis revealed that MTDH expression was significantly 
      associated with worse disease-free survival (DFS) and overall survival (OS) rates 
      in patients with LSCC (both p < 0.001). When lymph node metastasis and MTDH 
      expression were considered together, patients with lymph node metastasis and high 
      MTDH expression had both poorer DFS and OS rates than others (both p < 0.001). 
      Finally, multivariate analysis demonstrated that MTDH expression was an 
      independent prognostic factor for both DFS and OS rates in patients with LSCC. 
      Strong MTDH expression was negatively correlated with a canonical 
      epithelial-mesenchymal transition molecule E-cadherin (p < 0.001) and positively 
      associated with proangiogenic protein vascular endothelial growth factor (p < 
      0.001). MTDH overexpression was tightly associated with more aggressive tumour 
      behaviour and a poor prognosis, indicating that MTDH is a valuable molecular 
      biomarker for LSCC progression.
CI  - Copyright (c) 2013 UICC.
FAU - Liu, Yong
AU  - Liu Y
AD  - Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central 
      South University, Changsha, Hunan, China.
FAU - Su, Zhongwu
AU  - Su Z
FAU - Li, Guo
AU  - Li G
FAU - Yu, Changyun
AU  - Yu C
FAU - Ren, Shuling
AU  - Ren S
FAU - Huang, Donghai
AU  - Huang D
FAU - Fan, Songqing
AU  - Fan S
FAU - Tian, Yongquan
AU  - Tian Y
FAU - Zhang, Xin
AU  - Zhang X
FAU - Qiu, Yuanzheng
AU  - Qiu Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130307
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Cadherins)
RN  - 0 (Cell Adhesion Molecules)
RN  - 0 (MTDH protein, human)
RN  - 0 (Membrane Proteins)
RN  - 0 (RNA-Binding Proteins)
RN  - 0 (Vascular Endothelial Growth Factor A)
SB  - IM
MH  - Biomarkers, Tumor
MH  - Cadherins/metabolism
MH  - Carcinoma, Squamous Cell/*metabolism/*mortality
MH  - Cell Adhesion Molecules/biosynthesis/*metabolism
MH  - Disease Progression
MH  - Disease-Free Survival
MH  - Epithelial-Mesenchymal Transition
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Laryngeal Neoplasms/*metabolism/*mortality
MH  - Lymphatic Metastasis
MH  - Male
MH  - Membrane Proteins
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local
MH  - Neoplasm Staging
MH  - RNA-Binding Proteins
MH  - Survival
MH  - Vascular Endothelial Growth Factor A/metabolism
EDAT- 2013/02/01 06:00
MHDA- 2013/07/26 06:00
CRDT- 2013/02/01 06:00
PHST- 2012/08/11 00:00 [received]
PHST- 2012/12/09 00:00 [revised]
PHST- 2013/01/09 00:00 [accepted]
PHST- 2013/02/01 06:00 [entrez]
PHST- 2013/02/01 06:00 [pubmed]
PHST- 2013/07/26 06:00 [medline]
AID - 10.1002/ijc.28071 [doi]
PST - ppublish
SO  - Int J Cancer. 2013 Aug 1;133(3):671-9. doi: 10.1002/ijc.28071. Epub 2013 Mar 7.